Viridian Therapeutics Secures PDUFA Date for Veligrotug, Reports Strong Cash Position and Key Phase 3 Data Readouts

summarizeSummary

Viridian Therapeutics announced a PDUFA target action date of June 30, 2026, for veligrotug, submitted an MAA to the EMA, and confirmed upcoming Phase 3 data readouts for elegrobart in Q1 and Q2 2026, all supported by a strong cash position expected to fund the company through profitability.

check_boxKey Events

• Veligrotug PDUFA Target Date Set

  The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026, for veligrotug for thyroid eye disease (TED) under Priority Review, following positive pivotal results from THRIVE and THRIVE-2 studies.

• European Regulatory Submission for Veligrotug

  A Marketing Authorization Application (MAA) for veligrotug for TED was submitted to the European Medicines Agency (EMA) in January 2026, expanding the potential market.

• Upcoming Elegrobart Phase 3 Data Readouts

  Topline data from the Phase 3 REVEAL-1 study for elegrobart (VRDN-003) in active TED is on track for Q1 2026, with REVEAL-2 data in chronic TED expected in Q2 2026.

• Strong Cash Position and Runway

  The company reported $874.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and expects to fund current business plans through profitability with anticipated commercial revenues from veligrotug and elegrobart, if approved.

auto_awesomeAnalysis

This filing provides a comprehensive update on Viridian Therapeutics' pipeline and financial health. The establishment of a PDUFA target action date for veligrotug is a critical near-term catalyst, signaling a clear path to potential market entry. The concurrent submission of an MAA to the EMA expands the drug's global market opportunity. Furthermore, the anticipated topline data from two Phase 3 studies for elegrobart in Q1 and Q2 2026 represent significant upcoming milestones that could further de-risk the company's lead programs. The strong cash position, projected to fund operations through profitability with anticipated commercial revenues, provides a solid financial foundation for these advancements, mitigating concerns over increased R&D and SG&A expenses typical for a biotech in this stage.